Skip to content
10-Q

Quarterly Report

MAZE THERAPEUTICS, INC. MAZE

0000950170-25-071375

← back to feed
Filed
May 14, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 8, 2025 43.8M sh
Stockholders Equity Q1 2025 · Mar 31, 2025 $292.07M
Stockholders Equity Q1 2025 · Dec 31, 2024 −$311.18M
Current Liabilities Q1 2025 · Mar 31, 2025 $18.62M
Current Liabilities Q1 2025 · Dec 31, 2024 $20.67M
Total Liabilities Q1 2025 · Mar 31, 2025 $40.77M
Total Liabilities Q1 2025 · Dec 31, 2024 $43.64M
Current Assets Q1 2025 · Mar 31, 2025 $299.71M
Current Assets Q1 2025 · Dec 31, 2024 $201.67M
Total Assets Q1 2025 · Mar 31, 2025 $332.84M
Total Assets Q1 2025 · Dec 31, 2024 $240.54M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $196.81M
Cash And Equivalents Q1 2025 · Mar 31, 2024 $30.02M
Shares Diluted Q1 2025 · Mar 31, 2024 2.34M sh
Capex Q1 2025 · Mar 31, 2024 $279K
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$23.44M
Eps Diluted Q1 2025 · Mar 31, 2024 −$13.91
Eps Basic Q1 2025 · Mar 31, 2024 −$13.91
Sga Expense Q1 2025 · Mar 31, 2024 $6.14M
Rd Expense Q1 2025 · Mar 31, 2024 $21.88M
Net Income Q1 2025 · Mar 31, 2024 −$32.49M
Operating Income Q1 2025 · Mar 31, 2024 −$28.01M